Search
Please select the unit you wish to search and enter the keyword in the text field below.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.{br}{br}TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.{br}{br}Click “STAY” to return to tlcbio.com or “CONTINUE” to proceed.
LNP gene therapy drug
Description
LNP gene therapy drug
Development Status
Preclinical
Advantages
TLC501 is a cutting-edge gene therapy developed by TLC BioSciences, designed to promote the regeneration of chondrocytes by applying mRNA technology and LNP technology in one formulation, functioning as sustained proliferation stimulators. This innovative therapy is part of TLC's commitment to advancing treatments for osteoarthritis, aiming to maintain joint health and improve patient outcomes.
Indication
Chondrocyte generation
Preclinical ongoing
